5-alkynyl-pyrimidines

Abstract

The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

1 .- 15 . (canceled) 
     
     
         16 . A method of treating a disease comprising administering an effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein: 
       
         
           
           
               
               
           
         
         R 3  denotes a group selected from among 3-8 membered heterocycloalkyl, C 6-10 aryl and 5-12 membered heteroaryl, optionally substituted by one or more identical or different R 4 ; and 
         R 1  denotes a group selected from among C 6-10 aryl and 5-12 membered heteroaryl, optionally substituted by one or more identical or different R 5  and 
         R 2  denotes a group selected from among hydrogen, C 1-4 alkyl, C 3-8 cycloalkyl, 3-8 membered heteroalkyl, 3-8 membered heterocycloalkyl, —OR v , —NR v R v1 , —SR v , —CF 3 , 
         —CN, —NC and —NO 2 , and 
         each R 4  denotes a group selected from among R a  and R b ; and 
         each R a  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, R a  optionally being substituted by one or more identical or different R b  and/or R c4 , 
         each R b  denotes a suitable group and is selected independently of one another from among ═O, —OR c , C 1-3 haloalkyloxy, —OCF 3 , —OCHF 2 , ═S, —SR c , ═NR c , ═NOR c , ═NNR c R c1 , ═NN(R g )C(O)NR c R c1 , —NR c R c1 , —ONR c R c1 , —N(OR c )R c1 , —N(R g )NR c R c1 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R c , —S(O)OR c , —S(O) 2 R c , —S(O) 2 OR c , —S(O)NR c R c1 , —S(O) 2 NR c R c1 , —OS(O)R c , —OS(O) 2 R c , —OS(O) 2 OR c , —OS(O)NR c R c1 , —OS(O) 2 NR c R c1 , —C(O)R c , —C(O)OR c , —C(O)SR c , —C(O)NR c R c1 , —C(O)N(R g )NR c R c1 , —C(O)N(R g )OR c , —C(NR g )NR c R c1 , —C(NOH)R c , —C(NOH)NR c R c1 , —OC(O)R c , —OC(O)OR c , —OC(O)SR c , —OC(O)NR c R c1 , —OC(NR g )NR c R c1 , —SC(O)R c , —SC(O)OR c , —SC(O)NR c R c , —SC(NR g )NR c R c1 , —N(R g )C(O)R c , —N[C(O)R c ][C(O)R c1 ], —N(OR g )C(O)R c , —N(R g )C(NR g1 )R c , —N(R g )N(R g1 )C(O)R c , —N[C(O)R c2 ]NR c R c1 , —N(R g )C(S)R c , —N(R g )S(O)R c , —N(R g )S(O)OR c , —N(R g )S(O) 2 R c , —N[S(O) 2 R c ][S(O) 2 R c1 ], —N(R g )S(O) 2 OR c , —N(R g )S(O) 2 NR c R c1 , —N(R g )[S(O) 2 ] 2 R c , —N(R g )C(O)OR c , —N(R g )C(O)SR c , —N(R g )C(O)NR c R c1 , —N(R g )C(O)NR g1 NR c R c1 , —N(R g )N(R g1 )C(O)NR c R c1 , —N(R g )C(S)NR c R c1 , —[N(R g )C(O)] 2 R c , —N(R g )[C(O)] 2 R c , —N{[C(O)] 2 R c }{[C(O) 2 R c1 }, —N(R g )[C(O)] 2 OR c , —N(R g )C(O)] 2 NR c R c , —N{[C(O)] 2 OR c }{[C(O)] 2 OR c1 }, —N{[C(O)] 2 NR c R c1 }{[C(O)] 2 NR c2 R c3 }, —[N(R g )C(O)] 2 OR c , —N(R g )C(NR g1 )OR c , —N(R g )C(NOH)R c , —N(R g )C(NR g1 )SR c , —N(R g )C(NR g1 )NR c R c1 , —N(R g )C(═N—CN)NR c R c1  and —N═C(R g )NR c R c1  and 
         each R c , R c1 , R c2 , R c3  and R c4  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, R c , R c1 , R c2 , R c3  and R c4  independently optionally being substituted by one or more identical or different R d  and/or R e4 , where R c  together with R g  and/or R c1  and/or R c2  and/or R c3  or R c2  together with R c3  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and 
         each R d  denotes a suitable group and is selected independently of one another from among ═O, —OR e , C 1-3 haloalkyloxy, —OCF 3 , —OCHF2, ═S, —SR e , ═NR e , ═NOR e , ═NNR e R e1 , ═NN(R g2 )C(O)NR e R e1 , —NR e R e1 , —ONR e R e1 , —N(R g2 )NR e R e1 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R e , —S(O)OR e , —S(O) 2 R e , —S(O) 2 OR e , —S(O)NR e R e1 , —S(O) 2 NR e R e1 , —OS(O)R e , —OS(O) 2 R e , —OS(O) 2 OR e , —OS(O)NR e R e1 , —OS(O) 2 NR e R e1 , —C(O)R e , —C(O)OR e , —C(O)SR e , —C(O)NR e R e1 , —C(O)N(R g2 )NR e R e1 , —C(O)N(R g2 )OR e , —C(NR g2 )NR e R e1 , —C(NOH)R e , —C(NOH)NR e R e1 , —OC(O)R e , —OC(O)OR e , —OC(O)SR e , —OC(O)NR e R e1 , —OC(NR g2 )NR e R e1 , —SC(O)R e , —SC(O)OR e , —SC(O)NR e R e1 , —SC(NR g2 )NR e R e1 , —N(R g2 )C(O)R e , —N[C(O)R e ][C(O)R e1 ], —N(OR g2 )C(O)R e , —N(R 2 C(NR g3 )R e , —N(R g2 )N(R g3 )C(O)R e , —N[C(O)R e2 ]NR e R e1 , —N(R g2 )C(S)R e , —N(R g2 )S(O)R e , —N(R g2 )S(O)OR e —N(R g2 )S(O) 2 R e , —N[S(O) 2 R e ][S(O) 2 R e1 ], —N(R g2 )S(O) 2 OR e , —N(R g2 )S(O) 2 NR e R e1 , —N(R g2 )[S(O) 2 ] 2 R e , —N(R g2 )C(O)OR e , —N(R g2 )C(O)SR e , —N(R g2 )C(O)NR e R e1 , —N(R g2 )C(O)NR g3 NR e R e1 , —N(R g2 )N(R g3 )C(O)NR e R e1 , —N(R g2 )C(S)NR e R e1 , —[N(R g2 )C(O)][N(R g3 )C(O)]R e , 
         —N(R g2 )[C(O)] 2 R e , —N{[C(O)] 2 R e }{[C(O)] 2 R e1 }, —N(R g2 )[C(O)] 2 OR e , —N(R g2 )[C(O)] 2 NR e R e1 , —N{[C(O)] 2 OR e }{[C(O)] 2 OR e }, —N{[C(O)] 2 NR e R e1 }{[C(O)] 2 NR e2 R e3 }, —[N(R g3 )C(O)][N(R g3 )C(O)]OR e , 
         —N(R g )C(NR g3 )OR e , —N(R g )C(NOH)R e , —N(R g2 )C(NR g3 )SR e , —N(R g2 )C(NR g3 )NR e R e1 , —N(R g2 )C(═N—CN)NR e R e1  and —N═C(R g2 )NR e R e1    
         each R e , R e1 , R e2 , R e3  and R e4  independently of one another denotes hydrogen or a group selected from among C 4-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R e  together with R g2  and/or R e1  and/or R e2  and/or R e3  or R e2  together with R e3  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and where R e , R e1 , R e2 , R e3  and R e4  independently optionally being substituted by one or more identical or different R f  and/or R g6 , and 
         each R f  denotes a suitable group and in each case is selected independently of one another from among ═O, —OR g , C 1-3 haloalkyloxy, —OCF 3 , —OCHF 2 , ═S, —SR g , ═NR g4 , ═NOR g4 , ═NNR g4 R g5 , ═NN(R h )C(O)NR g4 R g5 , —NR g4 R g5 , —ONR g4 R g5 , 
         —N(R h )NR g4 R g5 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R g4 , —S(O)OR g4 , —S(O) 2 R g4 , —S(O) 2 OR g4 , —S(O)NR g4 R g5 , —S(O) 2 NR g4 R g5 , —OS(O)R g4 , —OS(O) 2 R g4 , —OS(O) 2 OR g4 , —OS(O)NR g4 R g5 , —OS(O) 2 NR g4 R g5 , —C(O)R g4 , —C(O)OR g4 , —C(O)SR g4 , —C(O)NR g4 R g5 , —C(O)N(R h )NR g4 R g5 , —C(O)N(R h )OR g4 , —C(NR h )NR g4 R g5 , —C(NOH)R g4 , 
         —C(NOH)NR g4 R g5 , —OC(O)R g4 , —OC(O)OR g4 , —OC(O)SR g4 , —OC(O)NR g4 R g5 , —OC(NR h )NR g4 R g5 , —SC(O)R g4 , —SC(O)OR g4 , —SC(O)NR g4 R g5 , —SC(NR h )NR g4 R g5 , —N(R h )C(O)R g4 , —N[C(O)R g4 ] 2 , —N(OR h )C(O)R g4 , —N(R h )C(NR h1 )R g4 , —N(R h )N(R h1 )C(O)R g4 , —N[C(O)R g6 ]NR g4 R g5 , —N(R h )C(S)R g4 , —N(R h )S(O)R g4 , —N(R h )S(O)OR g4 , —N(R h )S(O) 2 R g4 , —N[S(O) 2 R g4 ][S(O) 2 R g5 ], —N(R h )S(O) 2 R g4 , —N(R h )S(O) 2 NR g4 R g5 , —N(R h )[S(O) 2 ] 2 R g4 , —N(R h )C(O)OR g4 , —N(R h )C(O)SR g4 , —N(R h )C(O)NR g4 R g5 , —N(R h )C(O)NR h1 NR g4 R g5 , —N(R h )N(R h1 )C(O)NR g4 R g5 , —N(R h )C(S)NR g4 R g5 , —[N(R h )C(O)][N(R h1 )C(O)]R g4 , —N(R h )[C(O)] 2 R g4 , —N{[C(O)] 2 R g4 }{[C(O)] 2 R g5 }, —N(R h )[C(O)] 2 OR g4 , —N(R h )[C(O)] 2 NR g4 R g5 , —N{[C(O)] 2 OR 4 }{[C(O)] 2 OR g4 }, 
         —N{[C(O)] 2 NR g4 R g5 }{[C(O)] 2 NR g4 R g5 }, —[N(R h )C(O)][N(R h1 )C(O)]OR g4 , —N(R h )C(NR h1 )OR g4 , —N(R h )C(NOH)R g4 , —N(R h )C(NR h1 )SR g4 , —N(R h )C(NR h1 )NR g4 R g5 , —N(R h )C(═N—CN)NR g4 R g5  and —N═C(R h )NR g4 R g5 ; and 
         each R g , R g1 , R g2 , R g3 , R g4 , R g5  and R g6  independently of one another denotes hydrogen or a group selected from among C 4-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R g  together with R g1  and/or R h  may form a 3-8 membered cycloalkyl or a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and where R g , R g1 , R g2 , R g3 , R g4 , R g5  and R g6  independently optionally being substituted by one or more identical or different R h2 ; and 
         each R h , R h1  and R h2  is selected independently of one another from among hydrogen, C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R h  together with R h1  may form a 3-8 membered cycloalkyl or a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and 
         each R 5  denotes a group selected from among R m  and R n ; and 
         each R m  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-6 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, and R m  optionally substituted by one or more identical or different R n  and/or R o4 , 
         each R n  denotes a suitable group and is selected independently of one another from among ═O, —OR o , C 1-3 haloalkyloxy, —OCF 3 , —OCHF 2 , ═S, —SR o , ═NR o , ═NOR o , ═NNR o R o1 , ═NN(R s )C(O)NR o R o1 , —NR o R o1 , —ONR o R o1 , —N(OR o )R o1 , —N(R s )NR o R o1 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R o , —S(O)OR o , —S(O) 2 R o , —S(O) 2 OR o , —S(O)NR o R o1 , —S(O) 2 NR o R o1 , —OS(O)R o , —OS(O) 2 R o , —OS(O) 2 OR o , —OS(O)NR o R o1 , —OS(O) 2 NR o R o1 , —C(O)R o , —C(O)OR o , —C(O)SR o , —C(O)NR o R o1 , —C(O)N(R s )NR o R o1 , —C(O)N(R s )OR o , —C(NR s )NR o R o1 , —C(NOH)R o , —C(NOH)NR o R o1 , —OC(O)R o , —OC(O)OR o , —OC(O)SR o , —OC(O)NR o R o1 , —OC(NR s )NR o R o1 , —SC(O)R o , —SC(O)OR o , —SC(O)NR o R o , —SC(NR s )NR o R o1 , —N(R s )C(O)R o , —N[C(O)R o ][C(O)R o1 ], —N(OR s )C(O)R o , —N(R s )C(NR s1 )R o , —N(R s )N(R s1 )C(O)R o , —N[C(O)R o2 ]NR o R o1 , —N(R s )C(S)R o , —N(R s )S(O)R o , —N(R s )S(O)OR o , —N(R s )S(O) 2 R o , —N[S(O) 2 R o ][S(O) 2 R o1 ], —N(R s )S(O) 2 OR o , —N(R s )S(O) 2 NR o R o1 , —N(R s )[S(O) 2 ] 2 R o , —N(R s )C(O)OR o , —N(R s )C(O)SR o , —N(R s )C(O)NR o R o1 , —N(R s )C(O)NR s1 NR o R o1 , —N(R s )N(R s1 )C(O)NR o R o1 , —N(R s )C(S)NR o R o1 , —[N(R s )C(O)] 2 R o , —N(R s )[C(O)] 2 R o , —N{[C(O)] 2 R o }{[C(O)] 2 R o1 }, —N(R s )[C(O)] 2 OR, —N(R s )[C(O)] 2 NR o R o1 , —N{[C(O)] 2 OR o }{[C(O)] 2 OR o1 }, 
         —N{[C(O)] 2 NR o R o1 }{[C(O)] 2 NR o2 R o3 }, —[N(R s )C(O)] 2 OR o , —N(R s )C(NR s1 )OR o , —N(R s )C(NOH)R o , —N(R s )C(NR s1 )SR o , —N(R s )C(NR s1 )NR o R o1  and —N═C(R s )NR o R o1  and each R o , R o1 , R o2  and R o3  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R o  together with R o1  and/or R s  and/or R c1  and/or R c2  and/or R c3  or R c2  together with R c3  may form a 3-8 membered mono- or bicyclic heterocyclalkyl residue via a shared C-, N-, O- or S-atom, or where R o  together with R o1  may form a 3-14 membered spirocyclic heterocyclalkyl residue via a shared C-, N-, O- or S-atom and where R o , R o1 , R o2  and R o3  independently optionally being substituted by one or more identical or different R P  and/or R q4 , and 
         each R P  denotes a suitable group and is selected independently of one another from among ═O, —OR q , C 1-3 haloalkyloxy, —OCF 3 , —OCHF 2 , ═S, —SR q , ═NR q , ═NOR q , ═NNR q R q1 , ═NN(R s )C(O)NR q R q1 , —NR q R q1 , —ONR q R q1 , —N(R s )NR q R q1 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R q , —S(O)OR q , —S(O) 2 R q , —S(O) 2 OR q , —S(O)NR q R q1 , —S(O) 2 NR q R q1 , —OS(O)R q , —OS(O) 2 R q , —OS(O) 2 OR q , —OS(O)NR q R q1 , —OS(O) 2 NR q R q1 , —C(O)R q , —C(O)OR q , —C(O)SR q , —C(O)NR q R q1 , —C(O)N(R s )NR q R q1 , —C(O)N(R s )OR q , —C(NR s )NR q R q1 , —C(NOH)R q , —C(NOH)NR q R q1 , —OC(O)R q , —OC(O)OR q , —OC(O)SR q , —OC(O)NR q R q1 , —OC(NR s )NR q R q1 , —SC(O)R q , —SC(O)OR q , —SC(O)NR q R q1 , —SC(NR s )NR q R q1 , —N(R s )C(O)R q , —N[C(O)R q ][C(O)R q1 ], —N(OR s )C(O)R q , —N(R s )C(R s1 )R q , —N(R s )N(R s1 )C(O)R q , —N[C(O)R q2 ]NR q R q1 , —N(R s )C(S)R q , —N(R s )S(O)R q , —N(R s )S(O)OR q , —N(R s )S(O) 2 R q , —N[S(O) 2 R q ][S(O) 2 R q1 ], —N(R s )S(O) 2 OR q , —N(R s )S(O) 2 NR q R q1 , —N(R s )[S(O) 2 ] 2 R q , —N(R s )C(O)OR q , —N(R s )C(O)SR q , —N(R s )C(O)NR q R q1 , —N(R s )C(O)NR s1 NR q R q1 , —N(R s )N(R s1 )C(O)NR q R q1 , —N(R s )C(S)NR q1 , —[N(R s )C(O)][N(R g1 )C(O)]R q , —N(R s )[C(O)] 2 R q , —N{[C(O)] 2 R q }{[C(O)] 2 R q1 }, —N(R s )[C(O)] 2 OR q , —N(R s )[C(O)] 2 NR q R q1 , —N{[C(O)] 2 OR q }{[C(O)] 2 OR q1 }, —N{[C(O)] 2 NR q R q1 }{[C(O)] 2 NR q2 R q3 }, —[N(R s )C(O)][N(R s1 )C(O)]OR q , —N(R s )C(NR s1 )OR q , —N(R s )C(NOH)R q , —N(R s )C(NR s1 )SR q , —N(R s )C(NR s1 )NR q R q1 , —N(R s )C(═N—CN)NR q R q1  and —N═C(R s )NR q R q1 , and 
         each R 1 , R q1 , R q2 , R q3  and R q4  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R q  together with R q1  and/or R q2  and/or R q3  and/or R s  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, wherein R q , R q1 , R q2 , R q3  and R q4  are optionally independently substituted by one or more identical or different R r  and/or R s4 , and 
         each R r  denotes a suitable group and in each case is selected independently of one another from among ═O, —OR s , C 1-3 haloalkyloxy, —OCF 3 , —OCHF 2 , ═S, —SR s , ═NR s , ═NOR s , ═NNR s R s1 , ═NN(R t )C(O)NR s R s1 , —NR s R s1 , —ONR s R s1 , —N(R h )NR s R s1 , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , —N 2 , —N 3 , —S(O)R s , —S(O)OR s , —S(O) 2 R s , —S(O) 2 OR s , —S(O)NR s R s1 , —S(O) 2 NR s R s1 , —OS(O)R s , —OS(O) 2 R s , —OS(O) 2 OR s , —OS(O)NR s R s1 , —OS(O) 2 NR s R s1 , —C(O)R s , —C(O)OR s , —C(O)SR s , —C(O)NR s R s1 , —C(O)N(R t )NR s R s1 , —C(O)N(R t )OR s , —C(NR t )NR s R s1 , —C(NOH)R s , —C(NOH)NR s R s1 , —OC(O)R s , —OC(O)OR s , —OC(O)SR s , —OC(O)NR s R s1 , —OC(NR t )NR s R s1 , —SC(O)R s , —SC(O)OR s , —SC(O)NR s R s1 , —SC(NR t )NR s R s1 , —N(R t )C(O)R s , —N[C(O)R s ][C(O)R s1 ], —N(OR t )C(O)R s , —N(R t )C(NR t1 )R s , —N(R t )N(R t1 )C(O)R s , —N[C(O)R g2 ]NR s R s1 , —N(R t )C(S)R s , —N(R t )S(O)R s , —N(R t )S(O)OR s , —N(R t )S(O) 2 R s , —N[S(O) 2 R s ][S(O) 2 R s1 ], —N(R t )S(O) 2 OR s , 
         —N(R t )S(O) 2 NR s R s1 , —N(R t )[S(O) 2 ] 2 R s , —N(R t )C(O)OR s , —N(R t )C(O)SR s , —N(R t )C(O)NR s R s1 , —N(R t )C(O)NR t1 NR s R s1 , —N(R t )N(R t1 )C(O)NR s R s1 , —N(R t )C(S)NR s R s1 , —[N(R t )C(O)][N(R h1 )C(O)]R s , —N(R t )[C(O)] 2 R s , —N{[C(O)] 2 R s }{[C(O)] 2 R s1 }, —N(R t )[C(O)] 2 OR s , —N(R t )[C(O)] 2 NR s R s1 , —N{[C(O)] 2 OR s }{[C(O)] 2 OR s1 }, 
         —N{[C(O)] 2 NR s R s1 }{[C(O)] 2 NR s2 R s3 }, —[N(R t )C(O)][N(R t1 )C(O)]OR s , —N(R t )C(NR t1 )OR s , —N(R t )C(NOH)R s , —N(R t )C(NR t1 )SR s , —N(R t )C(NR t1 )NR s R s1 , —N(R t )C(═N—CN)NR s R s1  and —N═C(R t )NR s R s1 ; and 
         each R s , R s1 , R s2 , R s3  and R s4  independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R s  together with R s1  and/or R s2  and/or R s3  and/or R t  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, R s , R s1 , R s2 , R s3  and R s4  independently optionally being substituted by one or more identical or different R t2 ; and 
         each R t , R t1  and R t2  is selected independently of one another from among hydrogen, C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R t  together with R t1  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and 
         each R v  and R v1  is selected independently of one another from among hydrogen, C 1-6 alkyl, 2-6 membered heteroalkyl, C 1-8 haloalkyl, where R v  together with R v1  may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, 
         optionally in the form of the prodrugs, the tautomers, the racemates, the enantiomers, the diastereomers, the prodrugs and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof. 
       
     
     
         17 . The method of  claim 16  wherein said disease is a proliferative disease. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 16  wherein said disease is selected from a group consisting of cancer, infections, inflammatory and autoimmune diseases. 
     
     
         20 . The method of treating a disease selected from a group consisting of cancer, infections, inflammatory and autoimmune diseases, comprising administering an effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients and/or carriers, to a patient in need thereof. 
     
     
         21 . (canceled)